Cladribine tablets and multiple sclerosis: NICE technology appraisal

被引：0

作者：

Gaber, Tarek ^{[1
]}

Shippen, Clare ^{[2
]}

机构：

[1] Wrightington Wigan & Leigh NHS Fdn Trust, Neurol Rehabil, Wigan, England

[2] North West Deanery, Rehabil Med, Manchester, Lancs, England

来源：

PROGRESS IN NEUROLOGY AND PSYCHIATRY | 2018年 / 22卷 / 01期

关键词：

D O I：

10.1002/pnp.486

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Cladribine is the first disease modifying treatment (DMT) for relapsing remitting multiple sclerosis (RRMS) that progressed straight to a positive final recommendation in the NICE appraisal process. The final recommendations were published in December 2017.(1) An agreement between NHS England and Merck, the manufacturer of cladribine (Mavenclad), will allow MS patients who are suffering from highly active or rapidly evolving RRMS to access the drug. Here, the authors discuss the clinical and economic considerations for cladribine usage.

引用

页码：5 / 6

页数：2

共 50 条

[21] The design of the CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY)
Giovannoni, G.
Cook, S.
Rieckmann, P.
Vermersch, P.
Soelberg-Sorensen, P.
Comi, G.
Chang, P.
Lopez-Bresnahan, M.
Kim, R.
JOURNAL OF NEUROLOGY, 2006, 253 : 99 - 99
[22] Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Gavin Giovannoni
Joela Mathews
Neurology and Therapy, 2022, 11 : 571 - 595
[23] Long-term experience with cladribine tablets in multiple sclerosis patients
Oreja-Guevara, Celia
Gomez Estevez, Irene
Garcia Vasco, Lorena
Quezada Sanchez, Johnny
Diaz, Judit
Gil-Perotin, Sara Garcia
Alba Suarez, Elda Maria
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 966 - 966
[24] Study of B cells in subjects with multiple sclerosis treated with cladribine tablets
Pirronello, Marta
Picozza, Mario
Guerrera, Gisella
Corbisiero, Silvia
D'Orso, Silvia
Lista, Beatrice
Misiti, Andrea
Ruggieri, Serena
Quartuccio, Esmeralda
Buscarinu, Maria Chiara
De Masi, Francesca
Tortorella, Carla
Salvetti, Marco
Gasperini, Claudio
Borsellino, Giovanna
Battistini, Luca
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 641 - 642
[25] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
Cook, S.
Giovannoni, G.
Leist, T.
King, J.
Syed, S.
Nolting, A.
Schick, R.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 469 - 469
[26] Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets
Gasperini, Claudio
Ruggieri, Serena
Pozzilli, Carlo
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 391 - 399
[27] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
Cook, Stuart D.
Giovannoni, Gavin
Leist, Thomas P.
Syed, Sana
Nolting, Axel
Damian, Doris
Schick, Regina
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 54 - 55
[28] Cladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension study
Rieckmann, Peter
Giovannoi, Gavin
Cook, Stuart D.
Greenberg, S.
Chang, Peter
Comi, Giancarlo
Sorensen, Per Soelberg
Vermersch, Patrick
MULTIPLE SCLEROSIS, 2008, 14 : S161 - S162
[29] European experience of cladribine tablets in elderly multiple sclerosis: Could it be the last treatment ?
de Seze, Jerome
Zecca, Chiara
Castelnovo, Giovanni
Ayrignac, Xavier
Patrick, Vermersch
Gobbi, Claudio
Claudia, Mallucci
Dalliere, Clarisse Carra
Pierre, Labauge
Bigaut, Kevin
Laurent, Kremer
Collongues, Nicolas
Lanotte, Livia
Thouvenot, Eric
Ernon, Christine
Dive, Dominique
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 344 - 345
[30] Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis
Viglietta, V.
Greenberg, S.
Mikol, D.
Weiner, J.
Alteri, E.
Chang, P.
Krumwieh, D.
Musch, B.
JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S144

← 1 2 3 4 5 →